Table 4.
Participant demographics
| Characteristic | Total n = 8771 (%) | Initiation n = 4533 (%) | Switching n = 5165 (%) |
|---|---|---|---|
| Gender | |||
| F | 6,222 (71%) | 3,150 (69%) | 3,747 (73%) |
| M | 2,549 (29%) | 1,383 (31%) | 1,418 (27%) |
| Age category (years) | |||
| 0–20 | 326 (3.7%) | 257 (5.7%) | 147 (2.8%) |
| 21–30 | 1,682 (19%) | 1,130 (25%) | 841 (16%) |
| 31–40 | 2,556 (29%) | 1,386 (31%) | 1,455 (28%) |
| 41–50 | 2,318 (26%) | 1,011 (22%) | 1,490 (29%) |
| 51–60 | 1,392 (16%) | 520 (11%) | 944 (18%) |
| > 60 | 497 (5.7%) | 229 (5.1%) | 288 (5.6%) |
| Country | |||
| AU | 2,512 (29%) | 1,293 (29%) | 1,414 (27%) |
| AE | 30 (0.3%) | 15 (0.3%) | 18 (0.3%) |
| BE | 267 (3.0%) | 150 (3.3%) | 161 (3.1%) |
| CA | 627 (7.1%) | 228 (5.0%) | 447 (8.7%) |
| CO | 68 (0.8%) | 63 (1.4%) | 16 (0.3%) |
| EE | 70 (0.8%) | 34 (0.8%) | 45 (0.9%) |
| ES | 590 (6.7%) | 288 (6.4%) | 364 (7.0%) |
| GB | 38 (0.4%) | 13 (0.3%) | 29 (0.6%) |
| GR | 4 (< 0.1%) | 1 (< 0.1%) | 3 (< 0.1%) |
| HR | 309 (3.5%) | 234 (5.2%) | 121 (2.3%) |
| HU | 2 (< 0.1%) | 2 (< 0.1%) | 1 (< 0.1%) |
| IR | 429 (4.9%) | 163 (3.6%) | 294 (5.7%) |
| IT | 706 (8.0%) | 442 (9.8%) | 352 (6.8%) |
| JP | 94 (1.1%) | 70 (1.5%) | 43 (0.8%) |
| KW | 559 (6.4%) | 353 (7.8%) | 244 (4.7%) |
| LB | 45 (0.5%) | 20 (0.4%) | 31 (0.6%) |
| NL | 87 (1.0%) | 37 (0.8%) | 59 (1.1%) |
| NZ | 28 (0.3%) | 17 (0.4%) | 14 (0.3%) |
| OM | 53 (0.6%) | 23 (0.5%) | 37 (0.7%) |
| Other | 107 (1.2%) | 72 (1.6%) | 40 (0.8%) |
| PL | 1 (< 0.1%) | 1 (< 0.1%) | 0 (0%) |
| PT | 50 (0.6%) | 12 (0.3%) | 39 (0.8%) |
| TN | 103 (1.2%) | 74 (1.6%) | 47 (0.9%) |
| TR | 1,991 (23%) | 927 (20%) | 1,346 (26%) |
| US | 1 (< 0.1%) | 1 (< 0.1%) | 0 (0%) |
| MS course | 1,293 (29%) | ||
| Relapsing remitting | 7,610 (87%) | 3,906 (86%) | 4,570 (88%) |
| Secondary progressive | 537 (6.1%) | 113 (2.5%) | 443 (8.6%) |
| Primary progressive | 303 (3.5%) | 253 (5.6%) | 66 (1.3%) |
| Progressive relapsing | 95 (1.1%) | 60 (1.3%) | 42 (0.8%) |
| Radiologically isolated syndrome | 4 (< 0.1%) | 3 (< 0.1%) | 2 (< 0.1%) |
| Clinically isolated syndrome | 222 (2.5%) | 198 (4.4%) | 42 (0.8%) |
| EDSS | 2.37 (1.88) | 1.99 (1.67) | 2.64 (1.96) |
| Relapse count (in previous 24 months) | |||
| 0 | 4,708 (54%) | 2,016 (44%) | 3,005 (58%) |
| 1 | 2,847 (32%) | 1,790 (39%) | 1,478 (29%) |
| 2 | 918 (10%) | 570 (13%) | 498 (9.6%) |
| 3 | 228 (2.6%) | 126 (2.8%) | 137 (2.7%) |
| 4 | 46 (0.5%) | 23 (0.5%) | 28 (0.5%) |
| 5 | 16 (0.2%) | 7 (0.2%) | 12 (0.2%) |
| 6 | 3 (< 0.1%) | 1 (< 0.1%) | 2 (< 0.1%) |
| 7 | 4 (< 0.1%) | – | 4 (< 0.1%) |
| 10 | 1 (< 0.1%) | – | 1 (< 0.1%) |
| Disease duration (years) | 8.20 (8.31) | 4.44 (6.69) | 10.56 (8.34) |